[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients


Description

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.Screening Phase: Patients will be identified by clinical investigators at participating centers. Patients who sign the screening consent will undergo MRD assessment with the clonoSEQ® assay. If the assessment identifies the patient to be MRD negative, the patient will undergo a repeat MRD assessment ≥ 28 days later. If two consecutive MRD assessments indicate MRD-negativity, the patient will then sign the study intervention phase informed consent form and will undergo the rest of the screening process. Enrollment Once the patient fulfills all eligibility criteria, the patient will be enrolled into o

Trial Eligibility

Screening Phase Inclusion Criteria: * ≥ 18-years-old * Diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma confirmed by the enrolling institution * Receiving treatment or planning to receive treatment within 30 days with a venetoclax-based regimen as defined below: * Venetoclax monotherapy * Venetoclax in combination with anti CD20 monoclonal antibody (Patients must have completed the anti CD20 monoclonal antibody portion of the regimen prior to discontinuing therapy) * Patient has or will have specimen to identify the CLL or SLL clone(s) for future MRD assessments by clonoSEQ® defined as any of the following: * 3-5 bone marrow aspirate slides (banked), 3-5 FFPE slides (banked), banked tumor cells or banked DNA collected from the patient at any time from original diagnosis of CLL or SLL to present * Peripheral blood, marrow, or lymph node involvement for fresh sample collection * The screening ID sample (high disease burden sample) can be sent prior to start of venetoclax-based therapy to identify the clone for tracking. Study Intervention Phase Inclusion Criteria: * Patients must have received venetoclax-based therapy for at least 6 months (including dose interruptions) * If receiving venetoclax in combination with anti-CD20 monoclonal antibody, patients must have completed or discontinued the anti CD20 monoclonal antibody portion of the regimen prior to discontinuing therapy * Patients must have two MRD-negative assessments (defined by ≥ 10\^-5 sensitivity) on the peripheral blood by the clonoSEQ® assay at least 28 days apart. Given that MRD status is a dynamic endpoint which may improve with time, if a patient is screen failure based on MRD status (i.e. MRD positive at the 10-5 sensitivity), they may be rescreened to assess for study eligibility. * Patients must have achieved a complete or partial remission with the venetoclax-based regimen. Criteria for remission are per iwCLL 2018 guidelines. For this protocol, bone marrow biopsy/aspirate evaluation is not necessary to determine remission status. Exclusion Criteria (both study phases): * Ongoing participation in a clinical trial that supplies venetoclax and/or anti CD20 monoclonal antibody * Unwilling or unable to participate in all required study evaluations and procedures. * Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Study Info

Organization

Memorial Sloan Kettering Cancer Center


Primary Outcome

Proportion of patients able to remain off CLL/SLL directed therapy


Outcome Timeframe 2 years

NCTID NCT04419519

Phases PHASE2

Primary Purpose TREATMENT

Start Date 2020-05-13

Completion Date 2025-05

Enrollment Target 80

Interventions

DRUG Venetoclax monotherapy

DRUG Venetoclax with anti CD20 monoclonal antibody

Locations Recruiting

Memorial Sloan Kettering Basking Ridge (All protocol activities)

United States, New Jersey, Basking Ridge


Memorial Sloan Kettering Monmouth (All protocol activities)

United States, New Jersey, Middletown


Memorial Sloan Kettering Bergen (All protocol activities)

United States, New Jersey, Montvale


Memorial Sloan Kettering Commack (All protocol activities)

United States, New York, Commack


Memorial Sloan Kettering Westchester (All protocol activities)

United States, New York, Harrison


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Blood Cancer delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.